Safety of Arthritis Drugs, Day 2, Part 4
The Food and Drug Administration’s Arthritis and Drug Safety and Risk Management Advisory Committees continued discussions in their joint meeting on possible safety of risks of “COX-2” inhib…
500 viewsThe Food and Drug Administration’s Arthritis and Drug Safety and Risk Management Advisory Committees continued discussions in their joint meeting on possible safety of risks of “COX-2” inhib…
500 viewsPhysicians spoke at a meeting to assess the safety records of arthritis drugs. Representatives for the drug Lumiracoxib and for the Food and Drug Administration spoke. They also responded to…
159 views